Insufficient evidence to back medical cannabis for insomnia

by Cochrane

edited by Swati Mestri, reviewed by Robert Egan

Swati Mestri

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

The GIST Add to Preferred Sources

A new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.

Insomnia is a common sleep disorder that makes it hard to fall asleep or stay asleep and can leave people feeling unrefreshed when they wake up. It can have a severe impact on a person's quality of life and make them much more vulnerable to developing anxiety or depression over time.

Existing treatment options include cognitive behavioral therapy and drugs, including antidepressants and antipsychotics, but their effectiveness varies.

In recent years, there has been growing interest in medical cannabis as an alternative treatment for insomnia because of its reported benefits in improving sleep. In clinical settings, this typically involves controlled, tested ratios of THC and CBD in the form of tablets, sprays or oils. However, the use of medical cannabis for insomnia remains contentious, and evidence is limited.

No clear evidence that medical cannabis helps

Led by researchers from The Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and the University of Manitoba, the review included nine studies involving 537 adults ages 18 to 76 who were treated for insomnia. Most studies focused on people with primary insomnia rather than insomnia linked to other health conditions. Eight of the nine trials compared regulated medical cannabis with a placebo; one compared it with the antidepressant amitriptyline.

Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time or daytime functioning compared with placebo.

Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as dry mouth and dizziness, than those on placebo, but this finding was based on a small pool of studies.

Medical cannabis somewhat improved quality of life, but the certainty of the evidence is very low, and pooled results were compatible with anything from a slight worsening to a large improvement.

"The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia," says Dr. Lucia Varela, lead author of the study from the University of Manitoba, Canada. "This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population."

Poor trials downgrade the evidence

The overall quality and certainty of the evidence were rated very low to low, largely due to risk of bias in the underlying studies, inconsistent results between trials and small sample sizes.

Studies varied a lot in the type of cannabis product used, which limited comparability, and the longest study followed participants for only 12 weeks. This means we can't say much about the long-term effects.

The available data were also not very representative of broader patient groups. The data were heavily skewed toward younger people and women (72.66% of participants). Therefore, the findings may not be as applicable to men, older adults and those with comorbidities.

The authors conclude that the evidence remains weak and uncertain, highlighting the need for higher-quality research before medical cannabis can be recommended for insomnia.

"The evidence is too weak and uncertain to draw firm conclusions about the use of medical cannabis for insomnia," says Dr. Luis Garegnani, senior author from Universidad Hospital Italiano de Buenos Aires, Argentina. "Rather than viewing the findings as either an endorsement or a rejection of medical cannabis, clinicians and patients should recognize the uncertainty and consider individual circumstances while better evidence is generated."

Publication details

Medical cannabis for the treatment of insomnia, Cochrane Database of Systematic Reviews (2026). DOI: 10.1002/14651858.CD016216.pub2

Journal information: Cochrane Library

Key medical concepts

Medical MarijuanaInsomniaSleep Quality

Clinical categories

Sleep medicineSleep & RecoveryClinical pharmacology Provided by Cochrane Who's behind this story?

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Insufficient evidence to back medical cannabis for insomnia (2026, October 12) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-insufficient-evidence-medical-cannabis-insomnia.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.